Academic lecture of JNU College of Life Science and Technology, National Engineering Research Center of Genetically Engineered Drug, and Key Laboratory of Biological Engineering Drugs in Guangdong Province

Topic: Drugging “Undruggable” Oncogenic Proteins: our stories on targeting survivin and STAT3
Lecture | May 26, 2017 | 10:00 a.m. | room 701 in second building of Science and Technology

Speaker: Zhang Jian-ting, Indiana University
Host: Shi Zhi, Jinan University
Sponsors: JNU College of Life Science and Technology, National Engineering Research Center of Genetically Engineered Drug, Key Laboratory of Biological Engineering Drugs in Guangdong Province

ABOUT ZHANG JIAN-TING
Zhang Jian-ting now serves as Professor of Department of pharmacology and Toxicology in School of Medicine of Indiana University, Andrew and Peggy Thomson Visiting Professor of Hematology and Oncology Department of Simon Cancer Center. His main research areas are tumor occurrence and progression mechanisms, and anti-drug development. He has published more than 100 papers in professional journals including PNAS、Cell Res、Cancer Res、Clinical Cancer Res、Oncogene, applied 9 patents with 3 having been authorized, and assigned the three patents to many enterprises like Abcam、Novus Biologicals. He worked on more than 20 research funds including 5 R01 funds from National Institutes of Health, reaching a total sum of more than 100 million dollars. He is now a chief of Int J Biochem Mol Bioeditor, and editorial board member of PLoS One、Am J Trans Res、Mol Membr Bio